Scarica l'app Stockscreener
0.4333
4.38%
0.0182
Dopo l'orario di chiusura:
.43
-0.0033
-0.76%
Precedente Chiudi:
$0.4151
Aprire:
$0.42
Volume 24 ore:
677.64K
Relative Volume:
1.44
Capitalizzazione di mercato:
$28.53M
Reddito:
-
Utile/perdita netta:
$-151.16M
Rapporto P/E:
-0.1459
EPS:
-2.97
Flusso di cassa netto:
$-130.08M
1 W Prestazione:
-4.79%
1M Prestazione:
-10.75%
6M Prestazione:
-74.05%
1 anno Prestazione:
-92.77%
Intervallo 1D:
$0.4103
$0.4575
Intervallo di 1 settimana:
$0.404
$0.4666
Portata 52W:
$0.404
$8.78
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Nome
Alx Oncology Holdings Inc
Settore
Industria
Telefono
650-466-7125
Indirizzo
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Confronta ALXO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
0.4333 | 28.53M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2024-03-08 | Downgrade | Stifel | Buy → Hold |
| 2023-12-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-12-22 | Downgrade | Jefferies | Buy → Hold |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-06 | Iniziato | UBS | Buy |
| 2021-02-10 | Iniziato | H.C. Wainwright | Buy |
| 2020-08-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-08-11 | Iniziato | Credit Suisse | Outperform |
| 2020-08-11 | Iniziato | Jefferies | Buy |
| 2020-08-11 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Alx Oncology Holdings Inc Borsa (ALXO) Ultime notizie
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
ALX Oncology Confirms Directors at Annual Meeting - TipRanks
ALX Oncology reports annual meeting results By Investing.com - Investing.com Nigeria
ALX Oncology reports annual meeting results - Investing.com
Cantor Fitzgerald Weighs in on ALX Oncology FY2026 Earnings - Defense World
ALX Oncology (NASDAQ:ALXO) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Nuveen Asset Management LLC Has $275,000 Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Acquired by Two Sigma Investments LP - Defense World
Bank of America Corp DE Grows Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Acquired by Deutsche Bank AG - Defense World
Northern Trust Corp Acquires 23,324 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference - GlobeNewswire
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference | ALXO Stock News - GuruFocus
ALX Oncology Management to Showcase Novel Cancer Treatment Advances at Major Jefferies Healthcare Conference - Stock Titan
D. E. Shaw & Co. Inc. Decreases Stock Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
H.C. Wainwright maintains ALX Oncology stock Buy rating By Investing.com - Investing.com India
H.C. Wainwright maintains ALX Oncology stock Buy rating - Investing.com
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and ALX Oncology Holdings (ALXO) - The Globe and Mail
UBS Group Issues Pessimistic Forecast for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World
Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
ALXO: UBS Maintains 'Buy' Rating, Lowers Price Target | ALXO Sto - GuruFocus
ALXO: UBS Maintains 'Buy' Rating, Lowers Price Target | ALXO Stock News - GuruFocus
UBS Adjusts Price Target on ALX Oncology Holdings to $1 From $1.20, Maintains Buy Rating - marketscreener.com
ALX Oncology presents preclinical data, plans for ALX-2004 - BioWorld MedTech
UBS Adjusts Price Target for ALX Oncology (ALXO) to $1 | ALXO St - GuruFocus
UBS Adjusts Price Target for ALX Oncology (ALXO) to $1 | ALXO Stock News - GuruFocus
Transcript : ALX Oncology Holdings Inc.Special Call - marketscreener.com
ALX Oncology : Investor Presentation ALX2004 Webcast May 20 2025 Final (2a4ce1) - marketscreener.com
ALX Oncology Holdings Inc. Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event - marketscreener.com
ALXO Unveils Advanced Antibody-Drug Conjugate ALX2004 for Tumor Treatment | ALXO Stock News - GuruFocus
ALX Oncology Highlights Differentiated Design, Preclinical - GlobeNewswire
First-in-Class Cancer Drug: ALX Oncology's Novel EGFR-ADC Gets FDA Green Light for Clinical Trials - Stock Titan
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Sold by Cubist Systematic Strategies LLC - Defense World
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EG - GuruFocus
ALX Oncology to Host R&D Webcast Event Highlighting its - GlobeNewswire
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 - Stock Titan
HC Wainwright Issues Pessimistic Forecast for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World
ALXO Stock: HC Wainwright & Co. Lowers Price Target | ALXO Stock News - GuruFocus
ALX Oncology Reports Q1 2025 Financial Results - TipRanks
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
ALXO Advances Cancer Therapy Focus and Pipeline Development | AL - GuruFocus
ALXO Advances Cancer Therapy Focus and Pipeline Development | ALXO Stock News - GuruFocus
ALX ONCOLOGY Earnings Results: $ALXO Reports Quarterly Earnings - Nasdaq
Financial Health Check: Examining Alx Oncology Holdings Inc (ALXO)’s Key Ratios - DWinneX
ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ALX Oncology to Report First Quarter 2025 Financial Results on M - GuruFocus
ALX Oncology Holdings Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Will ALXO Make A Comeback In July? - RTTNews
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 | ALXO Stock News - GuruFocus
Alx Oncology Holdings Inc Azioni (ALXO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alx Oncology Holdings Inc Azioni (ALXO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Pons Jaume | PRESIDENT & CSO |
Feb 19 '25 |
Sale |
1.15 |
1,326 |
1,525 |
579,388 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
1.15 |
2,159 |
2,483 |
170,270 |
| Pinto Shelly | Interim CFO |
Jan 06 '25 |
Sale |
1.80 |
2,221 |
3,998 |
87,902 |
| Pinto Shelly | Interim CFO |
Dec 30 '24 |
Sale |
1.58 |
1,426 |
2,253 |
90,123 |
| Pons Jaume | PRESIDENT & CSO |
Dec 30 '24 |
Sale |
1.58 |
10,796 |
17,060 |
580,714 |
| Hemrajani Rekha | Director |
Dec 02 '24 |
Buy |
1.55 |
30,000 |
46,404 |
33,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 14 '24 |
Sale |
2.58 |
564 |
1,455 |
91,549 |
| Randolph Sophia | CHIEF MEDICAL OFFICER |
Aug 14 '24 |
Sale |
2.58 |
1,365 |
3,522 |
325,711 |
| Pons Jaume | PRESIDENT & CSO |
Aug 14 '24 |
Sale |
2.58 |
1,937 |
4,997 |
591,510 |
| Pons Jaume | PRESIDENT & CSO |
Jul 11 '24 |
Option Exercise |
0.99 |
20,000 |
19,800 |
613,447 |
0.39%
0.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):